Summary
Already effective 2025-10-01: the initial and renewal criteria were updated for moderate-to-severe atopic dermatitis, moderate-to-severe asthma, COPD, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis, and the initial length of approval changed from 6 months to 12 months. Prior authorization is required, and the use of samples by an individual will not be considered current or stable therapy to satisfy policy requirements. Dupixent (dupilumab) will be obtained through a BCBSMS network DSP-pharmacy.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.